Introduction
The variable clinical efficacy of typical and atypical antipsychotic drugs in the treatment of schizophrenia may be due to inter-individual variability in their binding to the dopamine D2 receptor family (D2, D3 and D4). The atypical antipsychotic drug clozapine, often successfully employed in the therapy of resistant schizophrenia, exhibits-in contrast to typical antipsychotics-a 10-fold higher affinity to the D4 receptor (DRD4) than to D2 and D3 receptors. 1 Although a clinical trial with a pure selective D4 agent has, to our knowledge, not yet been undertaken, results with a mixed sigma/D4 partial agonist 2 and with the mixed D4/5HT2A antagonist fananserin 3 do not support the hypothesis that the clinical effect of clozapine may be Correspondence: Dr J Brockmöller, Institut fü r Klinische Pharmakologie, Charité, Humboldt-Universität, Schumannstrasse 20/21, D-10098 Berlin, Germany. E-mail: jurgen.brockmollerȰ charite.de Received 18 August 1999; revised and accepted 15 December 1999 mediated by its moderately selective antagonism. However, this does not exclude a joint effect in conjunction with other receptors, since balanced action on several receptors may be a therapeutic principle.
The coding DNA sequence of the DRD4 4 is highly polymorphic, resulting in functionally different receptor variants. There is one rare 13-bp deletion resulting in a truncated protein with complete absence of functional receptor. 5 A known 48-bp imperfect tandem repeat (48-bp VNTR) in the third exon, with 2-10 repeats, results in a different length of the third cytoplasmatic loop. 6, 7 This part of the DRD4 is involved in G-protein coupling, with the consequence that this 48-bp VNTR may be functionally important. Under certain experimental conditions, there was a difference in clozapine binding, according to the number of repeat units. 7, 8 Expression studies in different cell lines showed that the potency of dopamine to inhibit cAMP formation was reduced about twofold in the D 4,7 variant, when compared with both the D 4.4 and the D 4.2 .
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A number of clinical studies 10, 11 have confirmed, and others have denied, the association between different alleles of the 48-bp repeat and the response to antipsy-chotic drug treatment. [12] [13] [14] The DRD4 receptor has also been investigated for possible linkage to schizophrenia, since DRD4 density was found in post-mortem brain tissues of schizophrenic patients 15 which was six times greater than that among non-psychiatric controls. Most studies investigating schizophrenia have not been able to find significant association of the DRD4 48-bp VNTR. 5, [16] [17] [18] [19] [20] [21] [22] [23] Most of them, however, have examined only small sample sizes. We therefore studied the population frequencies of the 48-bp repeat region in a large Caucasian population composed of schizophrenic patients, healthy subjects, and non-psychiatric patients. In accordance with the observations of Asghari et al, 8, 9 van Tol et al, 7 and Cohen et al, 11 we grouped all individuals carrying DRD4 48-bp VNTR genotypes with Յ 4-repeat alleles (genotypes: 14, 22, 23, 24, 33, 34, 44 ) and Ն 5-repeat alleles (all other genotypes as shown in Table 1 ), and all individuals carrying only Յ 4-repeat alleles with Ն 5-repeat alleles. We were primarily interested in the relation between therapeutic response and the 48-bp VNTR in patients treated with clozapine, as well as in patients treated with typical antipsychotics.
Subjects and materials

Subjects
We recruited 638 schizophrenic patients (54.6% male, 45.2% female; median age = 37 years (range = 18-70, SD: 12.2) and median age of onset = 27 years (range = 12-66 years, SD: 9.5) from two university psychiatric hospitals in Berlin: From the Charité University Medical Centre (n = 83), from the Benjamin Franklin University Medical Centre (n = 225), and from two general psychiatric hospitals, the Wilhelm-Griesinger Krankenhaus (n = 167) and Hospital Am Waldsee (n = 164). The schizophrenic males had a lower mean age of onset than did the females (26.4 years, range = 14-66 years, vs 31.5 years for the females, range = 15-61 years, P Ͻ 0.001, Mann-Whitney test). Only subjects of German Caucasian extraction were included.
The included cases were acute hospitalised patients with schizophrenia according to DSM-IV, 24 with breakdown as schizo-paranoid (n = 397; 295.3), schizoaffective (n = 109; 295.7), residual (n = 38; 295.6), catatonic (n = 32; 295.2), disorganised (n = 12; 295.1), schizophrenic form (n = 15; 295.4), undifferentiated (n = 7; 295.9), and miscellaneous (n = 28). Diagnosis was assigned on the basis of interviews and medical records according to the DSM-IV criteria. All psychiatrists involved in the study received detailed instruction how to use the DSM-IV criteria prior to the study and the diagnoses were regularly reviewed by a senior psychiatrist. Age at first episode, duration, familial predisposition, current therapeutic response, and medication were documented.
Only about one fifth of the patients were incident cases with their first acute episode of probable schizophrenia (n = 99); 518 suffered from a recurrent exacerbation. From the remaining 21 patients, it was not possible to obtain reliable medical history. Of 638 patients,
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182 had relatives with diagnosis of a psychiatric illness (depression, alcohol dependence, and various other psychiatric diagnoses), but only 50 had first-line relatives with schizophrenia.
Therapeutic response within the 5-week period of clinical surveillance for patients was evaluated twice: as global clinical assessment by the attending psychiatrist for patients receiving typical antipsychotics (partial or complete n = 360 or no remission n = 67) and clozapine (partial or complete n = 136 or no remission n = 36), and by application of the Positive and Negative Symptom Scale (PANSS). 25 Inter-rater reliability was assured by regular monthly meetings of the clinicians, in which one schizophrenic patient was interviewed as described by Kay et al 25 and was independently rated by the investigators of this study. All clozapine-treated patients were non-responders or poor responders to typical antipsychotics. Daily clozapine doses varied between 50 and 800 mg. The attending psychiatrists were blind to the patients' genotype.
We excluded patients with organic or drug-induced psychosis, as revealed by case history, magnetic-resonance tomography, computerised tomography data, or by positive toxicological findings. Patients younger than 18 or older than 70, and patients who left hospital within 7 days after admission, were likewise excluded.
As controls we recruited 474 healthy subjects (82.3% male, 17.7% female; median age = 28 years, range = 18-58 years, SD: 6.9) and 278 patients with various nonmalignant and non-psychiatric diseases (61.5% male, 38.5% female; median age = 70 years, range = 31-92 years, SD: 12.6). No controls had a history of psychiatric illness, substance abuse, or treatment with psychotropic drugs. Informed consent was obtained from all subjects. The study was approved by the ethics committee of the Charité University Medical Centre (Humboldt-Universität zu Berlin) and of the Benjamin Franklin University Medical Centre (Freie Universität Berlin).
Methods
High-molecular-weight genomic DNA was prepared from venous blood using standard phenol chloroform extraction. Genotyping was carried out using a PCRbased method modified according to Lichter et al. 6 PCR was performed in a total volume of 25 l containing 100 ng DNA, 1 M of each primer, 1 × buffer (Perkin Elmer, Roche, USA), 1.5 mM Mg 2+ , 10% DMSO, and 1 unit of Ampli Taq polymerase (Perkin Elmer, Branchburg, USA). dNTP were replaced by 200 M dATP, dCTP, dTTP, 100 M dGTP, and 100 M 7-deaza-GTP (Boehringer Mannheim, Mannheim, Germany). Primer sequences were 5Ј-GCG ACT ACG TGG TCT ACT CG-3Ј and 5Ј-AGG ACC CTC ATG GCC TTG-Ј3. DNA was denaturated at 99°C for 1 min prior to addition of other components. The PCR program consisted of 40 cycles; initial denaturation at 95°C for 20 s, followed by 57°C for 30 s, then 72°C for 1 min; and a final extension period at 72°C for 7 min using a GeneAmp 9600 PerkinElmer Cetus PCR machine. Laboratory staff were blind to psychiatric observations. All PCR products were 
Sequence analysis
The 48-bp VNTR was sequenced with a Taq-Dyedeoxy-terminator-cycle-sequencing kit (Applied Biosystems, Warrington, UK). Fragments were cut from the gel, purified by 0.45-m Ultrafree and 30 000 NMWL filter units (Millipore, Bedford, USA), and sequenced with 5Ј TGG CAC GTC GCG CCA AGC TGC AC 3Ј as upper and 5Ј CTG CGG GTC TGC GGT GGA GTC TG Ј3 as lower primer. Analysis took place on a ABI 373A automated sequencer and compared with the published sequence.
Statistical methods
Statistical analysis was performed with a SAS version 6.12. Significance of frequency differences of the combined genotypes or alleles was assessed by Pearson's 2 test or-in case of any cell counts less than 5-by Fisher's exact test. The limit of significance was set to 0.05. Basing on the observation of Asghari et al, 8, 9 van Tol et al, 7 and Cohen et al, 11 we grouped all genotypes with alleles Յ4 (14, 22, 23, 24 , 33, 34, 44) and alleles Ն5, or we grouped only the alleles Յ4 and Ն5. Statistics for PANSS was carried out using SPSS version 8.01. Table 1 shows the frequencies of the DRD4 48-bp VNTR genotypes for the schizophrenic patients and for the controls. In this sample of 1390 genotyped individuals, we found all numbers of repeats between 1 and 10 ( Figure 1 ), resulting in a total of 25 genotypes. The most common genotype was 44 (45.0%), followed by 47 (22.9%), and 24 (10.8%). A similar ranking was found world-wide, although allele frequencies differed among different ethnic groups of Africans, Asians, and Caucasians. 27 Only one schizophrenic individual carried the D 4.1 allele, and only one other patient had the D 4.10 allele. Sequencing of the 1-repeat allele identified a repeat of 48-bp described as zeta (, CCCCGCGCCCGGCCTCCCCCCGGACCCCTGCGGCTCC AACTGTGCTCC) according to Lichter et al. 6 As shown in Table 1 , differences in the dopamine D4 receptor genotype frequencies between all cases and controls were small and not statistically significant. We moreover found no significant difference in the allele frequencies (Table 2 ) between all schizophrenic patients and all controls. Comparison of the subgroup of patients having first-line relatives probably suffering from schizophrenia (n = 50) with all controls disclosed no significant difference. Likewise, comparison of those cases with relatives suffering from any type of psychiatric disease with all controls showed no difference. There was no difference in the frequencies of the allele combinations between incident and prevalent cases. We established significant differences neither within the case group among the schizo-paranoid, schizophreniforme, schizo-affective, and residual subgroups (DSM-IV 295.3, 295.4, 295.7, 295.6), nor among each of these subgroups compared with the total control group. However, as shown in Table 2 , patients with catatonic schizophrenia (295.2, n = 32) more frequently carried the D 4.2 (14.1%) and the D 4.3 alleles (10.9%) in comparison to all controls (8.4% and 4.1%, respectively), and compared with all other schizophrenic patients. The difference of the D 4.3 allele in comparison with the other cases (P = 0.002) or with the controls (P = 0.008) was significant.
Results
Combining these two alleles, we discovered significant differences in comparison with all other schizophrenic patients (25% vs 11.1%, P Ͻ 0.001, odds ratio =2.7, 95% confidence limits (CI) = 1.5-4.9, Bonferroni adjusted P Ͻ 0.01), and with controls (25.0% vs 12.5%, P Ͻ 0.004, odds ratio 2.3, CI = 1.3-4.2, Bonferroni adjusted P Ͻ 0.04). Eight of these patients were incident cases and all others were patients with recurrent *P = 0.07 compared with all other schizophrenic patients, P = 0.1 compared with controls; **P Ͻ 0.002 compared with all other schizophrenic patients; P Ͻ 0.008 compared with all controls; ***P = 0.1 compared with all other schizophrenic patients; P = 0.06 compared with controls; evaluated for the respective allele by chi-square test, not Bonferroni-corrected.
episodes. None of the patients with catatonic schizophrenia required intensive-care treatment. Therapeutic outcome as partial or complete, vs no remission among all schizophrenic patients, could not be correlated with genotypes or allele frequencies. Schizophrenic patients receiving typical antipsychotics or clozapine demonstrated no differences in their allele frequencies (Table 2 ) or genotypes (Table  1) in comparison between these two groups, or in separate comparison with all controls.
We found no significant differences for the frequency of genotypes (Table 1) between patients treated with typical antipsychotics vs patients treated with clozapine. The large number of 25 totally different genotypes was simplified by combining all those with any allele Յ4 repeats (14, 22, 23, 24, 33, 34, 44 ) vs the rest. There was no difference in the frequency of these two groups in comparison of clozapine-treated patients with those treated with typical antipsychotics. The therapeutic outcome measured as global assessment by the attending psychiatrist (Table 3) , or on the basis of the PANS scale (Table 4) , also did not differ with respect to these summarized DRD4 48-bp VNTR genotypes. For patients with catatonic schizophrenia we likewise found no differences.
Discussion
In the subgroup of patients with catatonic schizophrenia, we determined a substantial overrepresentation of the D 4.2 and D 4.3 allele. Patients with these alleles were accordingly 2.7 times more likely to develop catatonic schizophrenia compared to other types of schizophrenia.
The mechanisms behind the association between dopamine D4 receptor variants and catatonia are unclear. Lysaker et al 28 point out that stable individual differences in personality exist among persons with schizophrenia. It may be speculated whether such personality differences may be linked with dopamine receptor variants.
We found no significant differences in comparison of the DRD4 genotypes (Table 1 ) and allele frequencies All data were percent of total within the respective group. ns = not significant (chi-square test), either within each group or with respect to controls.
( Table 2 ) between schizophrenic patients and the entire control group in concordance with other studies. 18, 20, 22, 23 In contrast, Sommer et al 23 reported that the 44 genotype was more prevalent in schizophrenic patients than in controls (42.6% vs 32.2%). Daniels and colleagues, 18 on the other hand, found an opposite tendency (35.8% vs 43.7%).
The large number of 10 different repeat alleles with 25 genotypes requires summarising analysis as perfor- Combined genotypes as described in Table 3 . Mean value of the difference with 95% confidence limits between enrolment in the study and after week 5 of treatment.
med in almost all other studies. Our summarizing classification (Tables 3 and 4 ) was based on the functional analyses of Asghari et al 8, 9 and van Tol et al 4, 7 but no significant differences with respect to therapeutic outcome or disease susceptibility were found. Similarly, we found no differences by applying other types of data summary used earlier such as the classification of Kotler et al 26 These experimental findings prompted several clinical investigations, including the study presented here. But since the overall role of the D4 receptor is not yet completely understood, the relationship between experimental findings and the susceptibility to individual diseases, or the reaction to drugs, is far from clearly elucidated. There are indeed inconsistencies among different clinical studies. Cohen et al 11 reported that schizophrenic individuals responding to typical antipsychotics less frequently carried the D 4.7 allele than clozapine responders or controls.
Among the large sample of patients studied in Berlin (treated with typical antipsychotics or clozapine), we were not able to find any differences in the frequencies of the D 4.7 allele or longer between responders and nonresponders. Moreover, detailed exploration of therapeutic success broken down according to positive, negative, or general psychopathological symptoms (PANSS) did not reveal any significant differences ( 29 who established no association among clozapinetreated patients with a similar frequency distribution of alleles and genotypes (as we determined in our sample).
In summary, the DRD4 exon 3 VNTR does not appear to represent a major susceptibility factor for schizophrenia. It furthermore does not appear useful as a parameter predicting therapeutic response to antipsychotic treatment. We found in patients with catatonic schizophrenia, however, a substantial overrepresentation of the D 4.2 and D 4.3 allele. The number of catatonic patients was small; further investigations are therefore necessary to confirm the correlation. Our findings nevertheless illustrate the fascinating perspectives of genetically substantiated molecular differential diagnosis in psychiatry.
